People · Operator
Named in public records as an officer, director or promoter · active 2009–2014 · Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Hyperion Therapeutics Inc | — | Pharmaceuticals | Series B | $67.9M | $271.7M | 2014 |
| Seattle Genetics Inc /Wa | — | Other | Series A | $11.5M | $173.3M | 2009 |
Daniel G. Welch at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel G. Welch on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Srinivas Akkaraju | 1 | 10 |
| James Healy | 1 | 8 |
| James I. Healy | 1 | 7 |
| Rob Hopfner | 1 | 6 |
| Jake Nunn | 1 | 5 |
| Daniel Perez | 1 | 5 |
| Bijan Salehizadeh | 1 | 5 |
| Jake R. Nunn | 1 | 4 |
| Franklin M. Berger | 1 | 4 |
| Lota S Zoth | 1 | 4 |
| Donald Santel | 1 | 4 |
| Felix Baker | 1 | 4 |
| DAVID GRYSKA | 1 | 3 |
| Gaurav Aggarwal | 1 | 3 |
| Robert Hopfner | 1 | 3 |
| Daniel F. Hoth | 1 | 2 |
| Donald J. Santel | 1 | 2 |
| Bijan R. Salehizadeh | 1 | 2 |
| Bo Jesper Hansen | 1 | 2 |
| Christine A. Nash | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.